Bifunctional Beta-2 Agonist Muscarinic Antagonist Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary disorders like asthma and COPD rely on separate β2 adrenergic receptor agonists and muscarinic receptor antagonists, which are cumbersome to formulate and combine effectively for triple therapy combinations.
Innovation Solution
Development of novel compounds with both β2 adrenergic receptor agonist and muscarinic receptor antagonist activities, allowing for a single molecule to provide bronchodilation through two independent modes of action, simplifying formulation and combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If separate β2 adrenergic receptor agonist and muscarinic receptor antagonist compounds are used for treating pulmonary disorders, then both bronchodilation mechanisms can be provided, but the formulation complexity increases and combination with other therapeutic agents becomes more difficult
Solution Approach 1:
The patent combines two separate pharmacologically active moieties into a single bifunctional compound. The compound contains both a β2 adrenergic receptor agonist portion and a muscarinic receptor antagonist portion covalently linked together, enabling dual mechanism of action in one molecule. This merging eliminates the need for separate formulations and simplifies combination therapy approaches.
Solution Approach 2:
The bifunctional compound serves multiple therapeutic functions simultaneously. It acts as both a β2 adrenergic receptor agonist and a muscarinic receptor antagonist through its single molecular structure, providing universal bronchodilation coverage through two independent mechanisms of action, thereby reducing the need for multiple separate agents.
2Reliability
If two separate compounds are used to achieve dual mechanism of action, then comprehensive therapeutic coverage is provided, but the number of compounds to be formulated and administered increases
Solution Approach 1:
The invention merges two distinct pharmacologically active compounds into one bifunctional molecule. The β2 adrenergic receptor agonist moiety and the muscarinic receptor antagonist moiety are covalently connected, allowing both therapeutic mechanisms to be delivered by a single compound rather than requiring administration of two separate substances.
Solution Approach 2:
The single bifunctional compound performs the roles of two separate drugs simultaneously. It provides comprehensive therapeutic coverage by engaging both β2 adrenergic receptor agonism and muscarinic receptor antagonism pathways, thereby maintaining reliable dual-mechanism therapy while reducing the quantity of distinct compounds from two to one.
3Adaptability or versatility
If separate bronchodilator compounds are administered, then independent modes of action are achieved, but the ease of co-formulation with other therapeutic agents decreases
Solution Approach 1:
The bifunctional compound consolidates two independent modes of action into one molecular entity. By covalently linking the β2 adrenergic receptor agonist and muscarinic receptor antagonist moieties, the invention enables both mechanisms to operate independently within a single compound, simplifying co-formulation processes with other therapeutic agents such as corticosteroids.
Solution Approach 2:
The multifunctional compound provides universal bronchodilation through two independent pharmacological mechanisms while presenting a single formulation target. This universality enhances ease of manufacture and co-formulation, as pharmaceutical developers need to optimize only one compound rather than coordinating the interaction of two separate drugs with other therapeutic agents.
Data Source
AI summary
This invention provides compounds of formula I:wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, W, a and b are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor antagonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.